A patient with BRAFV600E-mutated anaplastic thyroid cancer with metastatic disease

Maria E. Cabanillas; Jennifer R. Wang

doi:10.1007/978-3-030-61919-0_43

A patient with BRAFV600E-mutated anaplastic thyroid cancer with metastatic disease

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Anaplastic thyroid cancer (ATC) has an overall poor prognosis. In 2018, the US Food and Drug Administration approved a BRAF/MEK inhibitor combination, dabrafenib/trametinib, for BRAFV600E-mutated ATC, which has shown high response rates (69%) and improved survival and is now the standard of care in the USA. Rapid determination of the BRAFV600E status is part of the initial workup for all ATC patients, in addition to the assessment of the airway and staging. In patients where a complete resection cannot be achieved (the majority), chemoradiation can be offered. Those with BRAF mutations, however, may benefit from neoadjuvant dabrafenib/trametinib followed by surgery and chemoradiation.

Original language	English (US)
Title of host publication	Thyroid Cancer
Subtitle of host publication	A Case-Based Approach
Publisher	Springer International Publishing
Pages	391-396
Number of pages	6
ISBN (Electronic)	9783030619190
ISBN (Print)	9783030619183
DOIs	https://doi.org/10.1007/978-3-030-61919-0_43
State	Published - Dec 15 2020

Keywords

BRAF inhibitor
MEK inhibitor
Systemic therapy

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-030-61919-0_43

Cite this

@inbook{8c9823456c2a423c8a246a250131719b,

title = "A patient with BRAFV600E-mutated anaplastic thyroid cancer with metastatic disease",

abstract = "Anaplastic thyroid cancer (ATC) has an overall poor prognosis. In 2018, the US Food and Drug Administration approved a BRAF/MEK inhibitor combination, dabrafenib/trametinib, for BRAFV600E-mutated ATC, which has shown high response rates (69%) and improved survival and is now the standard of care in the USA. Rapid determination of the BRAFV600E status is part of the initial workup for all ATC patients, in addition to the assessment of the airway and staging. In patients where a complete resection cannot be achieved (the majority), chemoradiation can be offered. Those with BRAF mutations, however, may benefit from neoadjuvant dabrafenib/trametinib followed by surgery and chemoradiation.",

keywords = "BRAF inhibitor, MEK inhibitor, Systemic therapy",

author = "Cabanillas, {Maria E.} and Wang, {Jennifer R.}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2021.",

year = "2020",

month = dec,

day = "15",

doi = "10.1007/978-3-030-61919-0_43",

language = "English (US)",

isbn = "9783030619183",

pages = "391--396",

booktitle = "Thyroid Cancer",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - A patient with BRAFV600E-mutated anaplastic thyroid cancer with metastatic disease

AU - Cabanillas, Maria E.

AU - Wang, Jennifer R.

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2021.

PY - 2020/12/15

Y1 - 2020/12/15

N2 - Anaplastic thyroid cancer (ATC) has an overall poor prognosis. In 2018, the US Food and Drug Administration approved a BRAF/MEK inhibitor combination, dabrafenib/trametinib, for BRAFV600E-mutated ATC, which has shown high response rates (69%) and improved survival and is now the standard of care in the USA. Rapid determination of the BRAFV600E status is part of the initial workup for all ATC patients, in addition to the assessment of the airway and staging. In patients where a complete resection cannot be achieved (the majority), chemoradiation can be offered. Those with BRAF mutations, however, may benefit from neoadjuvant dabrafenib/trametinib followed by surgery and chemoradiation.

AB - Anaplastic thyroid cancer (ATC) has an overall poor prognosis. In 2018, the US Food and Drug Administration approved a BRAF/MEK inhibitor combination, dabrafenib/trametinib, for BRAFV600E-mutated ATC, which has shown high response rates (69%) and improved survival and is now the standard of care in the USA. Rapid determination of the BRAFV600E status is part of the initial workup for all ATC patients, in addition to the assessment of the airway and staging. In patients where a complete resection cannot be achieved (the majority), chemoradiation can be offered. Those with BRAF mutations, however, may benefit from neoadjuvant dabrafenib/trametinib followed by surgery and chemoradiation.

KW - BRAF inhibitor

KW - MEK inhibitor

KW - Systemic therapy

UR - http://www.scopus.com/inward/record.url?scp=85150127617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150127617&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-61919-0_43

DO - 10.1007/978-3-030-61919-0_43

M3 - Chapter

AN - SCOPUS:85150127617

SN - 9783030619183

SP - 391

EP - 396

BT - Thyroid Cancer

PB - Springer International Publishing

ER -

A patient with BRAFV600E-mutated anaplastic thyroid cancer with metastatic disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this